Art. -Nr.: HY-18007

ALW-II-41-27

Name: ALW-II-41-27
Brand: MedChemExpress
SKU: HY-18007
Price: 231.00 USD
Availability: InStock
Rating: 5 (32 reviews)

(Synonyms: Eph receptor tyrosine kinase inhibitor)

32 Cited Publications

Kundenbewertung

Based on 32 publication(s) in Google Scholar

ALW-II-41-27 is a Eph family tyrosine kinase inhibitor with an IC₅₀ of 11 nM for Eph2.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.33%
CAS. Nr.: 1186206-79-0
Formel: C₃₂H₃₂F₃N₅O₂S
Molecular Weight:607.69

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

ALW-II-41-27 Chemical Structure

CAS. Nr.: 1186206-79-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (32)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

ALW-II-41-27 is a Eph family tyrosine kinase inhibitor with an IC₅₀ of 11 nM for Eph2.

IC₅₀ & Target

IC50: 11 nM (Eph2)^[1]

Alle Ephrin Receptor Isoform-spezifische Produkte anzeigen :

EphB
EphA

Cellular Effect

Cell Line	Type	Value	Description	References
BaF3	EC₅₀	<500 nM Compound: 7	Inhibition of Tel fused Bcr-Abl expressed in mouse BA/F3 cells Inhibition of Tel fused Bcr-Abl expressed in mouse BA/F3 cells	[PMID: 19553108]
BaF3	EC₅₀	<500 nM Compound: 7	Inhibition of Tel fused Bmx expressed in mouse BA/F3 cells Inhibition of Tel fused Bmx expressed in mouse BA/F3 cells	[PMID: 19553108]
BaF3	EC₅₀	<500 nM Compound: 7	Inhibition of Tel fused EphA3 expressed in mouse BA/F3 cells Inhibition of Tel fused EphA3 expressed in mouse BA/F3 cells	[PMID: 19553108]
BaF3	EC₅₀	<500 nM Compound: 7	Inhibition of Tel fused FGR expressed in mouse BA/F3 cells Inhibition of Tel fused FGR expressed in mouse BA/F3 cells	[PMID: 19553108]
BaF3	EC₅₀	<500 nM Compound: 7	Inhibition of Tel fused FLT1 expressed in mouse BA/F3 cells Inhibition of Tel fused FLT1 expressed in mouse BA/F3 cells	[PMID: 19553108]
BaF3	EC₅₀	<500 nM Compound: 7	Inhibition of Tel fused Fms expressed in mouse BA/F3 cells Inhibition of Tel fused Fms expressed in mouse BA/F3 cells	[PMID: 19553108]
BaF3	EC₅₀	<500 nM Compound: 7	Inhibition of Tel fused KDR expressed in mouse BA/F3 cells Inhibition of Tel fused KDR expressed in mouse BA/F3 cells	[PMID: 19553108]
BaF3	EC₅₀	<500 nM Compound: 7	Inhibition of Tel fused Kit expressed in mouse BA/F3 cells Inhibition of Tel fused Kit expressed in mouse BA/F3 cells	[PMID: 19553108]
BaF3	EC₅₀	<500 nM Compound: 7	Inhibition of Tel fused Lyn expressed in mouse BA/F3 cells Inhibition of Tel fused Lyn expressed in mouse BA/F3 cells	[PMID: 19553108]
BaF3	EC₅₀	<500 nM Compound: 7	Inhibition of Tel fused Src expressed in mouse BA/F3 cells Inhibition of Tel fused Src expressed in mouse BA/F3 cells	[PMID: 19553108]

In Vitro

ALW-II-41-27 inhibits Ba/F3 cells transformed with Tel fusions of EphA3, Kit, Fms, KDR, FLT1, FGR, Src, Lyn, Bmx, and Bcr-Abl with an EC₅₀ below 500 nM. ALW-II-41-27 exhibits cross reactivity with Bcr-Abl. ALW-II-41-27 inhibits b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2, EphB3, Frk, Kit, Lck, p38α, p38β, PDGFRα, PDGFRβ, and Raf1 and many more demonstrating how introduction of the thiophene group can have a tremendous impact on kinase selectivity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1186206-79-0
Appearance Solid
Molecular Weight 607.69
Formel C₃₂H₃₂F₃N₅O₂S
Color White to light yellow
SMILES

CC1=C(NC(C2=CC(C3=CC=CS3)=CN=C2)=O)C=C(C(NC4=CC=C(CN5CCN(CC)CC5)C(C(F)(F)F)=C4)=O)C=C1
Synonyms

Eph receptor tyrosine kinase inhibitor
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (32)

All WB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma. [Abstract]

2022 Feb 2;7(1):33. PMID: 35105853
Nat Commun

Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. [Abstract]

2023 May 13;14(1):2756. PMID: 37179400
Nat Commun

Small extracellular vesicles secreted from senescent cells promote cancer cell proliferation through EphA2. [Abstract]

2017 Jun 6:8:15729. PMID: 28585531

ALW-II-41-27 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2017 Jun 6:8:15729. [Abstract]

EphA2 immunoprecipitates prepared from MCF-7 cells expressing ectopic EphA2 are immunoblotted with anti-phosphotyrosine and anti-EphA2 antibody. The indicated samples are treated with recombinant human ephrin-A1 (500 ng/mL) for 20 min. Eight-hour pre-treatment with the EphA2 inhibitor ALW-II-41-27 (100 nM) suppressed ephrin-A1-induced EphA2 phosphorylation.
Cell Death Dis

Y772 phosphorylation of EphA2 is responsible for EphA2-dependent NPC nasopharyngeal carcinoma growth by Shp2/Erk-1/2 signaling pathway. [Abstract]

2020 Aug 27;11(8):709. PMID: 32848131
Cell Death Dis

EPH receptor A2 governs a feedback loop that activates Wnt/β-catenin signaling in gastric cancer. [Abstract]

2018 Nov 19;9(12):1146. PMID: 30451837
J Neuroinflammation

Inhibition of Ephrin receptor signaling in the paraventricular nucleus attenuates psoriasis-like dermatitis via synaptic plasticity and immune homeostasis modulation. [Abstract]

2025 Sep 24;22(1):211. PMID: 40993793
Oncogene

Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers. [Abstract]

2017 Oct 5;36(40):5620-5630. PMID: 28581527

ALW-II-41-27 purchased from MedChemExpress. Usage Cited in: Oncogene. 2017 Oct 5;36(40):5620-5630. [Abstract]

C3-TAg cells are starved and stimulated for 0, 15 and 30 min with ephrin-A1-Fc (EphA2 ligand; 1 μg/mL) in the presence or absence of ALW-II-41-27 or NG-25 control. EphA2 is immunoprecipitated and products probed for tyrosine phosphorylation and EphA2. ALW-II-41-27 significantly reduces basal and ephrin-A1-Fc induced tyrosine phosphorylation.
Mater Des

2025 Oct 25;260:115016.
Mol Cancer Ther

EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. [Abstract]

2019 Apr;18(4):845-855. PMID: 30824612
Cells

EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma. [Abstract]

2021 Oct 26;10(11):2893. PMID: 34831119
Mol Cancer Res

Phosphorylation of PLCγ1 by EphA2 Receptor Tyrosine Kinase Promotes Tumor Growth in Lung Cancer. [Abstract]

2020 Nov;18(11):1735-1743. PMID: 32753469
Int Immunopharmacol

Icariin suppresses osteogenic differentiation and promotes bone regeneration in Porphyromonas gingivalis-infected conditions through EphA2-RhoA signaling pathway. [Abstract]

2024 Oct 9;143(Pt 1):113302. PMID: 39388889
Front Pharmacol

A Novel EphA2 Inhibitor Exerts Beneficial Effects in PI-IBS in Vivo and in Vitro Models via Nrf2 and NF-κB Signaling Pathways. [Abstract]

2018 Mar 27:9:272. PMID: 29662452

ALW-II-41-27 purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Mar 27:9:272. [Abstract]

ALW-II-41-27 activates Nrf2 signaling whereas inhibits NF-kB signaling in Trichinella spiralis-infected mice.
Sci Rep

Targeting the Akt-EphA2 axis and cell-cell adhesion enhances anoikis sensitivity in cancer cells. [Abstract]

2026 Jan 25;16(1):6197. PMID: 41582276
Sci Rep

Cooperative function of oncogenic MAPK signaling and the loss of Pten for melanoma migration through the formation of lamellipodia. [Abstract]

2024 Jan 17;14(1):1525. PMID: 38233537
Int J Cancer

EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice. [Abstract]

2019 Nov 1;145(9):2440-2449. PMID: 30957241
Int J Cancer

Mutated EPHA2 is a target for combating lymphatic metastasis in intrahepatic cholangiocarcinoma. [Abstract]

2019 May 15;144(10):2440-2452. PMID: 30412282
J Cell Mol Med

EphA2 promotes tumorigenicity of cervical cancer by up-regulating CDK6. [Abstract]

2021 Mar;25(6):2967-2975. PMID: 33586348
FASEB J

EphrinB2/ephB2-mediated myenteric synaptic plasticity: mechanisms underlying the persistent muscle hypercontractility and pain in postinfectious IBS. [Abstract]

2019 Dec;33(12):13644-13659. PMID: 31601124
FASEB J

Dynamic membrane proteome of adipogenic and myogenic precursors in skeletal muscle highlights EPHA2 may promote myogenic differentiation through ERK signaling. [Abstract]

2019 Apr;33(4):5495-5509. PMID: 30668921

ALW-II-41-27 purchased from MedChemExpress. Usage Cited in: FASEB J. 2019 Apr;33(4):5495-5509. [Abstract]

Western analysis of p-EPHA2, EPAH2, p-AKT, AKT, P-ERK, ERK protein expression in the treatment of ALW-II-41-27 or transfected with siEPHA2 in GM before myogenic differentiation.
Breast Cancer Res Treat

Molecular determinants of drug response in TNBC cell lines. [Abstract]

2020 Jan;179(2):337-347. PMID: 31655920
J Cancer Res Clin Oncol

Cancer-associated fibroblasts promote gastric tumorigenesis through EphA2 activation in a ligand-independent manner. [Abstract]

2018 Sep;144(9):1649-1663. PMID: 29948146

ALW-II-41-27 purchased from MedChemExpress. Usage Cited in: J Cancer Res Clin Oncol. 2018 Sep;144(9):1649-1663. [Abstract]

Western blot analysis of E-cadherin, Cytokeratin, N-cadherin and Snail in AGS cells treated with 1 µM of ALW-II-41-27.
Cancer Manag Res

Quantitative Tyrosine Phosphoproteomic Analysis of Resistance to Radiotherapy in Nasopharyngeal Carcinoma Cells. [Abstract]

2020 Dec 9:12:12667-12678. PMID: 33328764
Oncol Lett

ALW-II-41-27, an EphA2 inhibitor, inhibits proliferation, migration and invasion of cervical cancer cells via inhibition of the RhoA/ROCK pathway. [Abstract]

2022 Apr;23(4):129. PMID: 35251349
Oncol Lett

Role of EphA2-PI3K signaling in vasculogenic mimicry induced by cancer-associated fibroblasts in gastric cancer cells. [Abstract]

2019 Sep;18(3):3031-3038. PMID: 31452781
bioRxiv

2026 Jan 5.
bioRxiv

Post-Translational Modifications Remodel Proteome-Wide Ligandability. [Abstract]

2025 Aug 2:2025.07.31.667978. PMID: 40766426
bioRxiv

2025 Jun 16.
Heliyon

A multi-model approach identifies ALW-II-41-27 as a promising therapy for osteoarthritis-associated inflammation and endochondral ossification. [Abstract]

2024 Dec 4;10(23):e40871. PMID: 39717596
Research Square Print

October 27th, 2022.
bioRxiv

2020 Apr.
Oncotarget

EphA2 signaling is impacted by carcinoembryonic antigen cell adhesion molecule 1-L expression in colorectal cancer liver metastasis in a cell context-dependent manner. [Abstract]

2017 Nov 1;8(61):104330-104346. PMID: 29262644

ALW-II-41-27 purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Nov 1;8(61):104330-104346. [Abstract]

MC38-CT or -CC1-L cells are treated with 1 μM of DMSO, or the non-specific NG-25 or specific ALW-II-41-27 EPHA2 receptor inhibitor for indicated periods of time, followed by stimulation with EFNA1-Fc (2 μg/mL) in the last 15 min of treatments. Protein lysates are prepared and subjected to immunoblotting using antibodies to determine the effect of kinase inhibitors on EPHA2 activation.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 47 mg/mL (77.34 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6456 mL

8.2279 mL

16.4558 mL

5 mM

0.3291 mL

1.6456 mL

3.2912 mL

10 mM

0.1646 mL

0.8228 mL

1.6456 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (4.11 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Choi, et al. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters (2009), 19(15), 4467-4470. [Content Brief]

[2]. Song W, et al. Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers. Oncogene. 2017 Jun 5. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6456 mL	8.2279 mL	16.4558 mL	41.1394 mL
	5 mM	0.3291 mL	1.6456 mL	3.2912 mL	8.2279 mL
	10 mM	0.1646 mL	0.8228 mL	1.6456 mL	4.1139 mL
	15 mM	0.1097 mL	0.5485 mL	1.0971 mL	2.7426 mL
	20 mM	0.0823 mL	0.4114 mL	0.8228 mL	2.0570 mL
	25 mM	0.0658 mL	0.3291 mL	0.6582 mL	1.6456 mL
	30 mM	0.0549 mL	0.2743 mL	0.5485 mL	1.3713 mL
	40 mM	0.0411 mL	0.2057 mL	0.4114 mL	1.0285 mL
	50 mM	0.0329 mL	0.1646 mL	0.3291 mL	0.8228 mL
	60 mM	0.0274 mL	0.1371 mL	0.2743 mL	0.6857 mL

Bioz

Keywords

ALW-II-41-27

32 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

ALW-II-41-27

Publications Citing Use of MedChemExpress (MCE) ALW-II-41-27

Alle Ephrin Receptor Isoform-spezifische Produkte anzeigen